Skip to content
Clinical Trials – home
ItalyBack to Italy

Clinical trials in Florence – page 33

805 clinical trials in Florence, Italy across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Florence at a glance
805
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

805 trials in Florence

Open in trial search

Prostate cancer

Not yet recruiting

Study on Prostate Cancer: Comparing Stereotactic Body Radiation Therapy Alone or with Triptorelin and Bicalutamide for Patients with Acinar Cell Prostatic Carcinoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bicalutamide
  • Sponsor:Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia

Study Comparing ABP 692 and Ocrelizumab for Patients with Relapsing-Remitting Multiple Sclerosis

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Ocrelizumab
  • Sponsor:Amgen Inc.

Study on Pembrolizumab as Maintenance Therapy for Patients with Unresectable Stage III Non-Small Cell Lung Cancer After Chemo-Radiotherapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Universita' Degli Studi Di Torino

Diabetic foot

Not yet recruiting

Study on the Safety and Effects of Udonitrectag for Treating Diabetic Foot Ulcers in Patients

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:UDONITRECTAG
  • Sponsor:Mimetech S.r.l.

Non-small cell lung cancer

Not yet recruiting

Study on the Best Treatment Sequence for Advanced Non-Small Cell Lung Cancer with EGFR Mutations Using Dacomitinib and Osimertinib

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Dacomitinib
  • Sponsor:Fondazione Ricerca Traslazionale

Study on Durvalumab and Chemotherapy for Patients with Relapsed Stage III Non-Small Cell Lung Cancer After Chemoradiotherapy and Durvalumab Treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Fondazione Ricerca Traslazionale

Head and neck cancer

Not yet recruiting

Study on the Effects of Tepotinib and Cetuximab for Patients with Platinum-Resistant Head and Neck Cancer After Immunotherapy Relapse

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cetuximab
  • Sponsor:Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia

Study on Niraparib for Patients with Advanced Urothelial Cancer After Initial Platinum Chemotherapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Niraparib Tosilate Monohydrate
  • Sponsor:Universita' Degli Studi Di Torino

Acute myeloid leukaemia

Not yet recruiting

Study on the Safety and Effectiveness of Fludarabine and Treosulfan for Stem Cell Transplant in Acute Myeloid Leukemia Patients Aged 40 to 65

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Ciclosporin
  • Sponsor:Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia

Study on Alectinib for Patients with ALK+ Stage III Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Alectinib
  • Sponsor:GOIRC Gruppo Oncologico Italiano Di Ricerca Clinica

Non-small cell lung cancer+1

Not yet recruiting

Study of Niraparib and Dostarlimab for Patients with Advanced Non-Small Cell Lung Cancer or Malignant Pleural Mesothelioma with Specific Genetic Mutations

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Universita' Degli Studi Di Torino

Colon cancer stage III+1

Not yet recruiting

Study on Post-Surgery Treatment for Colon Cancer Patients Using Trifluridine, Irinotecan, and Drug Combination

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Fondazione GONO G.I.

Other cities in Italy

The busiest research cities in the country

All 234 cities in Italy

Clinical research in Florence

What the registry says about research in the country

01 Neurological Disorders

Clinical research focusing on innovative treatments for frontotemporal dementia, multiple sclerosis, and Dravet syndrome. Studies evaluate novel therapeutic approaches including DNL593 for FTD and frexalimab for relapsing MS.

  • Frontotemporal Dementia Treatment
  • Multiple Sclerosis Management
  • Seizure Control in Dravet Syndrome

Emphasis on safety assessment and long-term efficacy monitoring.

02 Oncology Research

Comprehensive studies targeting various cancer types including colorectal cancer, breast cancer, and lung cancer. Trials explore combination therapies and novel treatment approaches.

  • Metastatic Colorectal Cancer Treatment
  • Advanced Breast Cancer Therapies
  • NSCLC Post-Surgery Care

Focus on targeted therapies and personalized treatment approaches.

03 Autoimmune Conditions

Investigating treatments for psoriatic arthritis, Sjögren's syndrome, and systemic sclerosis. Research includes evaluation of new biologics and targeted therapies.

  • Psoriatic Arthritis Management
  • Sjögren's Syndrome Treatment
  • Systemic Sclerosis Interventions

Studies aim to improve quality of life and disease management.

04 Respiratory Medicine

Studies examining treatments for COPD and respiratory infections, including evaluation of tezepelumab for moderate to severe COPD and prevention of RSV in infants.

  • COPD Exacerbation Management
  • RSV Prevention in Infants
  • Respiratory Disease Therapies

Focus on improving respiratory outcomes and prevention strategies.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.